Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported third-quarter earnings that surpassed expectations, boosted by robust sales of its key innovative therapies and an improved full-year outlook. Shares surged more than 17% in intra-day trading on Wednesday. The company posted adjusted earnings of $0.78 per share, well above analyst forecasts of$0.68. Revenue rose 3% year over year to $4.48 billion, exceeding the$4.36 billion consensus estimate and representing 1% growth in local currency. Teva’s inn ...